The open-label trial plans to enroll 45 healthy adults aged 18 to 55 years over a six week period. The first study participant received the vaccine yesterday.
Researchers at Kaiser Permanente Washington Health Research Institute (KPWHRI) will evaluate different doses of the experimental vaccine for safety and its ability to induce immune responses. It is the first step in the clinical trial process to evaluating the benefit of a vaccine, according to the National Institutes of Health (NIH).
Filed Under: Drug Discovery, Drug Discovery and Development, Infectious Disease